2021 annual financial data
CytomX Therapeutics 2021 Operating cash flow margin
Direct answer
Operating cash flow margin was -171.09%.
Operating income was -83,781,000 USD and net income was -80,648,000 USD.
Operating cash flow was -119,031,000 USD.
Get free CytomX Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 69,573,000 USD
- Operating income
- -83,781,000 USD
- Net income
- -80,648,000 USD
- Operating cash flow
- -119,031,000 USD